Find a Doctor

Nassim Kamar
NK
Areas of Expertise

Nassim Kamar

Chu De Toulouse
Nephrology
Male

Bio

Nassim Kamar is a Nephrologist in Toulouse Cedex 9, France. He has been an author on 515 peer reviewed articles and participated in 6 clinical trials in the past 15 years.

Areas of Expertise

Contact

Toulouse Cedex 9, 31059, FR

33.05.61.32.39.89

Latest Advances

Latest Advance
Study
  • Condition: Post-Liver Transplantation
  • Journal: Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society
  • Treatment Used: Switch From Tacrolimus to Everolimus
  • Number of Patients: 143
  • Published —
This study evaluated liver transplant patients at month 1 after transplant to everolimus (EVR) with stepwise tacrolimus (TAC) withdrawal or to standard tacrolimus, both with basiliximab induction and mycophenolic acid ± steroids.
Latest Advance
Study
  • Condition: Transplant Recipients with Progressive Multifocal Leukoencephalopathy (PML)
  • Journal: Emerging infectious diseases
  • Treatment Used: Immune Checkpoint Inhibitors
  • Number of Patients: 3
  • Published —
This article discussed the effectiveness of immune checkpoint inhibitors in transplant recipients with progressive multifocal leukoencephalopathy (rare viral brain disease; PML).
Latest Advance
Study
  • Condition: Kidney Transplantation and Renal Epidemiology of Atypical Hemolytic Uremic Syndrome (HUS)
  • Journal: Journal of the American Society of Nephrology : JASN
  • Treatment Used: Highly Individualized Complement Blockade
  • Number of Patients: 126
  • Published —
This study evaluated the use of highly individualized complement blockade-based prophylaxis with eculizumab to prevent post-transplant atypical hemolytic uremic syndrome (HUS) recurrence.
Latest Advance
Study
  • Condition: ABO-incompatible kidney transplantation
  • Journal: Clinical transplantation
  • Treatment Used: Anti-IL-2R blockers versus polyclonal antibodies
  • Number of Patients: 97
  • Published —
The study researched the effects of Anti-IL-2R blockers versus polyclonal antibodies for ABO-incompatible kidney transplantation.
Latest Advance
Study
  • Condition: De Novo Kidney Transplant Patients
  • Journal: Kidney international
  • Treatment Used: Everolimus with Tacrolimus (TAC) or Cyclosporine (CsA) vs. Standard Immunosuppression
  • Number of Patients: 338
  • Published —
This study in de novo kidney transplant patients to compared everolimus versus mycophenolic acid (MPA) with similar tacrolimus exposure in both groups, or everolimus with concomitant tacrolimus or cyclosporine (CsA), in an un-selected population.
Latest Advance
Study
  • Condition: Skin Cancer
  • Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • Treatment Used: Sirolimus
  • Number of Patients: 120
  • Published —
This study tested the safety and efficacy of using sirolimus for reducing the rate of skin cancer recurrence in patients recovering from skin cancer.
Latest Advance
Study
  • Condition: recurrence of hepatitis C after liver transplantation
  • Journal: Hepatology (Baltimore, Md.)
  • Treatment Used: Ribavirin-free sofosbuvir and nonstructural protein 5A inhibitor regimen
  • Number of Patients: 699
  • Published —
The purpose of the study was determine whether liver transplant recipients could be treated with a sofosbuvir plus non structural protein 5A inhibitor based-regimen without ribavirin for 12 weeks post-liver transplantation
Latest Advance
Study
  • Condition: Kidney transplant
  • Journal: Transplantation
  • Treatment Used: Conversion to belatacept
  • Number of Patients: 219
  • Published —
This study evaluated the efficacy and safety of conversion to belatacept in kidney transplant patients.

Clinical Trials

Clinical Trial
  • Status: Recruiting
  • Phase: Phase 3
  • Intervention Type: Drug, Biological
  • Participants: 350
  • Start Date: October 14, 2019
A Pivotal Phase 3 Trial to Evaluate the Safety and Efficacy of Clazakizumab for the Treatment of Chronic Active Antibody-mediated Rejection in Kidney Transplant Recipients
Clinical Trial
  • Status: Recruiting
  • Phase: N/A
  • Intervention Type: Other
  • Participants: 115
  • Start Date: October 1, 2018
Specialized Proresolving Mediators Evaluation in Pneumocystis Pneumonia Human Infection : Pilot Study.
Clinical Trial
  • Status: Recruiting
  • Phase: N/A
  • Intervention Type: Procedure
  • Participants: 30
  • Start Date: May 2, 2018
Evaluation of 2 Techniques of Apheresis to Desensitize ABO Incompatible Kidney Transplant Candidates: Double Filtration PlasmaPheresis (DFPP) vs Large Plasma Volume Specific ImmunoAdsorption
Clinical Trial
  • Status: Recruiting
  • Phase: Phase 3
  • Intervention Type: Drug
  • Participants: 272
  • Start Date: March 5, 2018
L-carnitine as an Adjunct Treatment for Septic Shock Patients With Acute Kidney Injury: a Multicentre, Randomized, 2-parallel Group, Superiority Trial
Clinical Trial
  • Status: Recruiting
  • Phase: N/A
  • Intervention Type: Other
  • Participants: 180
  • Start Date: April 5, 2017
Impact of a Simple Clinical Tool for Increasing Enrollment on a Kidney Transplant Waiting List for Patients Aged Over 70 and Initiating Dialysis
Clinical Trial
  • Status: Recruiting
  • Phase: Phase 3
  • Intervention Type: Other, Drug
  • Participants: 346
  • Start Date: September 2015
Evaluation of a Strategy Based on the 3-month Screening Biopsy to Optimize the Immunosuppression in Renal Transplantation: the I4BiS Study

All Publications
View All

Publication
Study
  • Journal: Clinical transplantation
  • Published —
Comparison of Two Strategies Based On Mammalian Target of Rapamycin Inhibitors In Secondary Prevention of Non-Melanoma Skin Cancer After Kidney Transplantation, a Pilot Study.
Publication
Study
  • Journal: Therapeutic drug monitoring
  • Published —
Validation of a Capillary Dry Blood Sample MITRA-Based Assay for the Quantitative Determination of Systemic Tacrolimus Concentrations in Transplant Recipients.

Contact

Toulouse Cedex 9, 31059, FR

33.05.61.32.39.89

Insurance

Contact them to find out if they accept your insurance plan.